AN2 Therapeutics, Inc.(ANTX)

Biotechnology · Menlo Park, CA

$5.40-0.21 (-3.74%)

Delayed quote: Oct 6, 2026, 9:39 AM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T13:40:50.206Z.

Stored calculation inputs

Calculation as of: 2026-10-06T13:40:50.206Z.

Quote observation: 2026-10-06T13:39:13.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 5.4
Unrounded diluted TTM EPS · period ending 2026-06-30: -1.07

FMP input reference: 66e3eaee1cdd755dffe0dd2f4d89b3fc137545160e5faabf240127d9674bae42

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

ANTX PE Ratio Metrics

PE RATIO

N/A

ANTX Competitors' PE Ratio

ANTX

AN2 Therapeutics, Inc.

Current

Market Cap

$194.49M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ELDN

Eledon Pharmaceuticals, Inc.

vs ANTX

Market Cap

$194.51M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ETRA

Electra Therapeutics Inc.

vs ANTX

Market Cap

$202.16M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DERM

Journey Medical Corporation

vs ANTX

Market Cap

$184.12M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNTN

Canton Strategic Holdings Inc

vs ANTX

Market Cap

$180.08M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CUE

Cue Biopharma, Inc.

vs ANTX

Market Cap

$177.91M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CGEN

Compugen Ltd.

vs ANTX

Market Cap

$219.84M

PE Ratio

6.19

TTM Avg

6.53

3Y Avg

42.60

5Y Avg

42.60

DTIL

Precision BioSciences, Inc.

vs ANTX

Market Cap

$175.27M

PE Ratio

N/A

TTM Avg

11.57

3Y Avg

11.57

5Y Avg

11.57

CHRS

Coherus Oncology, Inc.

vs ANTX

Market Cap

$172.27M

PE Ratio

N/A

TTM Avg

5.36

3Y Avg

5.36

5Y Avg

8.25

CMPX

Compass Therapeutics, Inc.

vs ANTX

Market Cap

$171.10M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
AN2 Therapeutics, Inc. (ANTX)	$194.49M	N/A	N/A	N/A	N/A
Eledon Pharmaceuticals, Inc. (ELDN)vs ›	$194.51M	N/A	N/A	N/A	N/A
Electra Therapeutics Inc. (ETRA)vs ›	$202.16M	N/A	N/A	N/A	N/A
Journey Medical Corporation (DERM)vs ›	$184.12M	N/A	N/A	N/A	N/A
Canton Strategic Holdings Inc (CNTN)vs ›	$180.08M	N/A	N/A	N/A	N/A
Cue Biopharma, Inc. (CUE)vs ›	$177.91M	N/A	N/A	N/A	N/A
Compugen Ltd. (CGEN)vs ›	$219.84M	6.19	6.53	42.60	42.60
Precision BioSciences, Inc. (DTIL)vs ›	$175.27M	N/A	11.57	11.57	11.57
Coherus Oncology, Inc. (CHRS)vs ›	$172.27M	N/A	5.36	5.36	8.25
Compass Therapeutics, Inc. (CMPX)vs ›	$171.10M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$5.40

Forward EPS (Est.)

$-0.89

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

ANTX PE Ratio Metrics

ANTX Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics